Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol 2012 May 29;9(7):376-85
Date
05/30/2012Pubmed ID
22641164DOI
10.1038/nrurol.2012.106Scopus ID
2-s2.0-84863718973 (requires institutional sign-in at Scopus site) 32 CitationsAbstract
Prostate cancer remains a significant health problem for men in the Western world. Although treatment modalities are available, these do not confer long-term benefit and are accompanied by deleterious side effects. Immunotherapy represents a valuable alternative to conventional treatments by inducing tumour-specific immune responses that control the growth of cancer cells. Sipuleucel-T is approved by the FDA as an immunotherapeutic agent for the treatment of patients with asymptomatic or minimally symptomatic castration-resistant prostate cancer (CRPC). Although this approval has raised cost-versus-benefit issues, it has provided proof of concept for the therapeutic potential of active immunotherapy approaches for metastatic CRPC. Numerous clinical studies have demonstrated clinical benefit using immunotherapy compared to traditional chemotherapy and several active immunotherapy approaches (at various developmental stages)have demonstrated the potential to change the face of prostate cancer treatment.
Author List
Karan D, Holzbeierlein JM, Van Veldhuizen P, Thrasher JBAuthor
Dev Karan PhD Associate Professor in the Pathology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsClinical Trials as Topic
Humans
Immunotherapy
Male
Prostatic Neoplasms
Treatment Outcome
